Cecelia Koetting, OD: AbbVie/Allergan: Consulting Fees (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Consulting Fees (), Independent Contractor (including contracted research) (), Speaker's Bureau (honoraria or other compensation) (); Blephex: Consulting Fees (); bruder: Consulting Fees (); Dompe: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Glaukos: Consulting Fees (); harrow: Speaker's Bureau (honoraria or other compensation) (); Movu: Advisory Committee/Board Member (), Consulting Fees (); Myze: Consulting Fees (); nulids: Consulting Fees (); Topcon: Consulting Fees (); viatris: Speaker's Bureau (honoraria or other compensation) ()
Explore the latest in managing ocular floaters, from assessing patient impact to evaluating surgical and non-surgical treatment options, including laser vitreolysis and vitrectomy, to enhance visual outcomes and improve quality of life
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Understand the pathophysiology and clinical presentation of vitreous opacities, including their impact on visual function and quality of life.
Evaluate non-surgical treatment options for ocular floaters, such as observation and laser vitreolysis, and their indications.
Discuss surgical approaches, including pars plana vitrectomy, assessing risks, benefits, and patient selection criteria.
